Teva to shutter Montreal plant, cut 340 jobs; Baxter boosts earnings, raises outlook;

  @FiercePharma: Now that Brilinta's approved, AZ has to sell it. Story | Follow @FiercePharma

> Teva Pharmaceutical plans to shut down a Montreal plant acquired as part of its Ratiopharm buyout, having failed to find a buyer for the facility; the move will put 340 employees out of work. Report

> Baxter International reported higher-than-expected quarterly earnings, led by strong sales at its bioscience units, and raised its outlook for the full year. Report

> Prescriptions for Abbott Laboratories' Niaspan cholestserol drug fell 5% 6 weeks after a study that said the medicine failed to prevent heart attacks. Article

> Teva Pharmaceutical Industries said it settled patent litigation related to its generic versions of the Novartis blood-pressure drug Lotrel. News

> Express Scripts' takeover of Medco Health Solutions may fuel acquisitions of specialty pharmacy benefit managers by rivals seeking to gain enough size to negotiate lower prices with drugmakers. Report

> An FDA advisory panel backed an additional use of Johnson & Johnson's top-selling drug Remicade in pediatric patients, but said more data is needed about a rare cancer found in some young people treated with Remicade and similar drugs. Piece

> Danish drugmaker Lundbeck expects annual royalties from Japanese sales of its antidepressant Lexapro to peak in 6 or 7 years at above 500 million Danish crowns ($95.2 million). Item

> Shares of AmerisourceBergen fell 5% to $39.78 on worries that the company's lucrative contract with Medco Health Solutions could be in jeopardy now that it is being acquired by Express Scripts. News

> The FDA declared three pseudoephedrine-based medicines used to treat colds and allergies as controlled drugs. Report

> All strategic suppliers to Johnson & Johnson will need at least two publicly-reported sustainability goals under a new initiative by the healthcare giant. Report

Biotech News

@FierceBiotech: Roche could get groove back with potential early approvals of cancer drugs. Article | Follow @FierceBiotech

@JohnCFierce: The semagacestat Alzheimer's drug story demos again how little we know about consequences of messing with believed triggers. Item | Follow @JohnCFierce

 @RyanMFierce: Translational research is very difficult. Forbes lists the ways. Article | Follow @RyanMFierce

 @MaureenFierce: Experiments that insert human genes, cells into animals need rules to ensure they don't create 'monsters.' Article | Follow @MaureenFierce

> Bristol-Myers snapping up Amira Pharma for $325M. More

> Pfizer commits $100M to Mission Bay project. Story

And Finally... Lloyds pharmacy will open a pilot "health village" in a London retail center as part of its plan to become an all-round healthcare provider. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.